These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 31151906)

  • 41. The projected timeframe until cervical cancer elimination in Australia: a modelling study.
    Hall MT; Simms KT; Lew JB; Smith MA; Brotherton JM; Saville M; Frazer IH; Canfell K
    Lancet Public Health; 2019 Jan; 4(1):e19-e27. PubMed ID: 30291040
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Human papillomavirus (HPV) vaccination: from clinical studies to immunization programs.
    Murillo R; Ordóñez-Reyes C
    Int J Gynecol Cancer; 2019 Oct; 29(8):1317-1326. PubMed ID: 31455660
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.
    Bardach AE; Garay OU; Calderón M; Pichón-Riviére A; Augustovski F; Martí SG; Cortiñas P; Gonzalez M; Naranjo LT; Gomez JA; Caporale JE
    BMC Public Health; 2017 Feb; 17(1):152. PubMed ID: 28148228
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007-2016.
    Gallagher KE; Howard N; Kabakama S; Mounier-Jack S; Burchett HED; LaMontagne DS; Watson-Jones D
    Papillomavirus Res; 2017 Dec; 4():72-78. PubMed ID: 29179873
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HPV vaccination for cervical cancer prevention is not cost-effective in Japan.
    Isshiki T
    Asian Pac J Cancer Prev; 2014; 15(15):6177-80. PubMed ID: 25124594
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Should human papillomavirus vaccination target women over age 26, heterosexual men and men who have sex with men? A targeted literature review of cost-effectiveness.
    Soe NN; Ong JJ; Ma X; Fairley CK; Latt PM; Jing J; Cheng F; Zhang L
    Hum Vaccin Immunother; 2018; 14(12):3010-3018. PubMed ID: 30024823
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Implementation of a human papillomavirus vaccination demonstration project in Malawi: successes and challenges.
    Msyamboza KP; Mwagomba BM; Valle M; Chiumia H; Phiri T
    BMC Public Health; 2017 Jun; 17(1):599. PubMed ID: 28651574
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Assessment of the Broader Economic Consequences of HPV Prevention from a Government-Perspective: A Fiscal Analytic Approach.
    Setiawan D; Kotsopoulos N; Wilschut JC; Postma MJ; Connolly MP
    PLoS One; 2016; 11(8):e0160707. PubMed ID: 27490258
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
    Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
    Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    de Kok IM; van Ballegooijen M; Habbema JD
    J Natl Cancer Inst; 2009 Aug; 101(15):1083-92. PubMed ID: 19571256
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis.
    Simms KT; Laprise JF; Smith MA; Lew JB; Caruana M; Brisson M; Canfell K
    Lancet Public Health; 2016 Dec; 1(2):e66-e75. PubMed ID: 29253419
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.
    Li X; Stander MP; Van Kriekinge G; Demarteau N
    BMC Infect Dis; 2015 Dec; 15():566. PubMed ID: 26652918
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States.
    Brisson M; Laprise JF; Chesson HW; Drolet M; Malagón T; Boily MC; Markowitz LE
    J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26438574
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Age-based programs for vaccination against HPV.
    Elbasha EH; Dasbach EJ; Insinga RP; Haupt RM; Barr E
    Value Health; 2009; 12(5):697-707. PubMed ID: 19490561
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comprehensive approach to costing cervical cancer prevention and control: a case study in the United Republic of Tanzania using the Cervical Cancer Prevention and Control Costing (C4P) tool.
    Levin A; Yuma S; Swai E; Morgan W; Gauvreau CL; Broutet N; Yeung KHT; Hutubessy R
    BMC Med; 2022 Nov; 20(1):384. PubMed ID: 36316680
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK.
    Datta S; Pink J; Medley GF; Petrou S; Staniszewska S; Underwood M; Sonnenberg P; Keeling MJ
    BMC Infect Dis; 2019 Jun; 19(1):552. PubMed ID: 31234784
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The cost-effectiveness of male HPV vaccination in the United States.
    Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
    Vaccine; 2011 Oct; 29(46):8443-50. PubMed ID: 21816193
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative Cost-Effectiveness Analysis of Two Different Two-Dose Human Papillomavirus Vaccines in Malaysia.
    Van Kriekinge G; Sohn WY; Aljunid SM; Soon R; Yong CM; Chen J; Lee IH
    Asian Pac J Cancer Prev; 2018 Apr; 19(4):933-940. PubMed ID: 29693347
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Status of HPV vaccine introduction and barriers to country uptake.
    Gallagher KE; LaMontagne DS; Watson-Jones D
    Vaccine; 2018 Aug; 36(32 Pt A):4761-4767. PubMed ID: 29580641
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Increasing global accessibility to high-level treatments for cervical cancers.
    Chargari C; Arbyn M; Leary A; Abu-Rustum NR; Basu P; Bray F; Chopra S; Nout R; Tanderup K; Viswanathan AN; Zacharopoulou C; Soria JC; Deutsch E; Gouy S; Morice P
    Gynecol Oncol; 2022 Jan; 164(1):231-241. PubMed ID: 34716024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.